[B057] 牛眼图分析
获取牛眼图分析
检索条件中涉及的机构、靶点、适应症、药物类型默认都是向上卷积(Roll-Up)逻辑
请求参数
此 API 接口支持的参数列表
| 名称 | 类型 | 示例 | 描述 |
|---|---|---|---|
必填 | integer<int64> | 10 | 返回条数,默认10条。仅支持10,20,30 |
必填 | string | ORGANIZATION | 分析维度,枚举值:ORGANIZATION、TARGET、DISEASE、DRUG_TYPE、REGION |
| boolean | true | 分析结果是否向上卷积(Roll-up),仅分析维度为ORGANIZATION(机构)时生效,默认true |
| object | {
"value": [
"2838b95ade834c96b17ac8bcd2b68c27"
],
"condition": "OR"
} | 药物,condition默认为OR,不支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [
"2838b95ade834c96b17ac8bcd2b68c27"
] | 值列表 |
| object | {
"value": [],
"condition": "OR"
} | 药物类型,condition默认为OR,不支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [] | 值列表 |
| object | {
"value": [],
"condition": "OR"
} | 靶点,condition默认为OR,支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [] | 值列表 |
| object | {
"value": [],
"condition": "OR"
} | 作用机制,condition默认为OR,不支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [] | 值列表 |
| object | {
"value": [],
"condition": "OR"
} | 适应症,condition默认为OR,不支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [] | 值列表 |
| object | {
"value": [
"11ef8a9e8bf5ca80213a1183511cded3"
],
"condition": "OR"
} | 机构,condition默认为OR,不支持AND。 |
| string | OR | 逻辑运算符,枚举值:AND、OR, 大小写敏感。 |
| array | [
"11ef8a9e8bf5ca80213a1183511cded3"
] | 值列表 |
| array | [] | 最高研发状态。枚举值:Discovery、Preclinical、IND、IND_Approval、Early_Phase_1、Phase_1、Phase_1_2、Phase_2、Phase_2_3、Phase_3、NDA_BLA、Approved、Clinical、Pending、Discontinued、Withdraw、Suspended、Unknown。 |
| boolean | true | 是否存在药物交易 |
| array | [] | 研发状态。枚举值:Discovery、Preclinical、IND、IND_Approval、Early_Phase_1、Phase_1、Phase_1_2、Phase_2、Phase_2_3、Phase_3、NDA_BLA、Approved、Clinical、Pending、Discontinued、Withdraw、Suspended、Unknown。 |
| array | [
"US",
"EU"
] | 国家地区。枚举值:US、EU、JP、CN、Other |
| array | [
"Company"
] | 机构类型。枚举值:Company、University_Institution、Other |
| array | [
"GREATER_THAN_500"
] | 雇员数量。枚举值:LESS_THAN_10、BETWEEN_10_AND_100、BETWEEN_100_AND_500、GREATER_THAN_500 |
| boolean | - | 是否初创公司 |
响应结构
API 响应数据的结构说明
| 字段名 | 类型 | 示例 | 描述 |
|---|---|---|---|
data | object | - | 响应数据 |
items | array | Please check the form:BullEyesPlotDto | 查询结果 |
data | array | Please check the form:BullEyesPlotDto | 牛眼图具体数据 |
drug | array | [
{
"drug_id": "07bf6b38be634718897783feeabef441",
"drug_type": {
"display_name": [
{
"lang": "EN",
"name": "Biological products"
},
{
"lang": "CN",
"name": "生物药"
}
],
"normalized_id": "06bc75afc2f44364a9663730fa37c37a"
},
"display_name": [
{
"lang": "EN",
"name": "VRON-0200"
}
]
},
{
"drug_id": "e4cbc3790c5d4f299e8cd765585033ad",
"drug_type": {
"display_name": [
{
"lang": "EN",
"name": "Biological products"
},
{
"lang": "CN",
"name": "生物药"
}
],
"normalized_id": "06bc75afc2f44364a9663730fa37c37a"
},
"display_name": [
{
"lang": "EN",
"name": "Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)"
}
]
}
] | 药物信息 |
drug_id | string | e82b83b42eba4e5ea3f26f8e06081a5a | 药物ID |
drug_type | object | {
"display_name": [
{
"lang": "EN",
"name": "Biological products"
},
{
"lang": "CN",
"name": "生物药"
}
],
"normalized_id": "06bc75afc2f44364a9663730fa37c37a"
} | 药物类型,引用“CommonDictionary” |
display_name | array | [
{
"lang": "EN",
"name": "Autologous CAR-T"
},
{
"lang": "CN",
"name": "自体CAR-T"
}
] | 字典名称 |
lang | string | EN | 语言 |
name | string | Ranibizumab (Genentech) | 药物、靶点、机构、适应症、国家/地区、字典、作用机制 名称 |
normalized_id | string | 2fbfdb3e92d942c48cbb0adb79f23526 | 字典ID |
display_name | array | [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
},
{
"lang": "CN",
"name": "雷珠单抗"
}
] | 药物名称,引用“CommonName” |
un_know | array | [
"e4cbc3790c5d4f299e8cd765585033ad"
] | 未知药物类型的药物ID列表 |
stat_info | object | {
"drug_type": [
{
"display_name": [
{
"lang": "EN",
"name": "Biological products"
},
{
"lang": "CN",
"name": "生物药"
}
],
"normalized_id": "06bc75afc2f44364a9663730fa37c37a"
}
]
} | 统计信息 |
drug_type | array | [
{
"display_name": [
{
"lang": "EN",
"name": "Biological products"
},
{
"lang": "CN",
"name": "生物药"
}
],
"normalized_id": "06bc75afc2f44364a9663730fa37c37a"
}
] | 药物类型,引用“CommonDictionary” |
dev_status | object | {
"display_name": [
{
"lang": "EN",
"name": "Phase 1"
},
{
"lang": "CN",
"name": "临床1期"
}
],
"normalized_id": "e2c11c24a7ee4b4e81bbde9eb7127c6d"
} | 研发状态,引用“CommonDictionary” |
related_drug_id | array | [
"07bf6b38be634718897783feeabef441"
] | 关联的药物ID列表 |
target | object | [
{
"target_id": "e49efee164e537c2a4ba9cec109e0adb",
"short_name": [
{
"lang": "EN",
"name": "BCMA"
}
],
"display_name": [
{
"lang": "EN",
"name": "B-cell maturation protein"
},
{
"lang": "CN",
"name": "B细胞成熟蛋白"
}
]
}
] | 靶点,引用“CommonTarget” |
target_id | string | 1c2067e5ab054a8995f73efcfcf56207 | 靶点ID |
short_name | array | [
{
"lang": "EN",
"name": "VEGF"
}
] | 靶点简称,引用“CommonName” |
display_name | array | [
{
"lang": "EN",
"name": "Vascular endothelial growth factor"
},
{
"lang": "CN",
"name": "血管内皮生长因子"
}
] | 靶点全称,引用“CommonName” |
country | object | {
"country_id": "0dc5d896-7408-3c87-84c0-22e3d9b784be",
"alpha2_code": "US",
"display_name": [
{
"lang": "EN",
"name": "United States"
},
{
"lang": "CN",
"name": "美国"
}
]
} | 国家/地区,引用“CommonCountry” |
country_id | string | 676de5ba-893a-36bb-8683-c93306aaf769 | 国家地区ID |
alpha2_code | string | US | 国家编码 |
display_name | array | [
{
"lang": "EN",
"name": "United States"
},
{
"lang": "CN",
"name": "美国"
}
] | 国家地区名称 |
disease | object | {
"disease_id": "05554578204541148a5482ad5df4a600",
"display_name": [
{
"lang": "EN",
"name": "Glioblastoma Multiforme"
},
{
"lang": "CN",
"name": "多形性胶质母细胞瘤"
}
]
} | 适应症,引用“CommonDisease” |
disease_id | string | 06a9082fe1ec4c97bea31d888b9cfdce | 适应症ID |
display_name | array | [
{
"lang": "EN",
"name": "Uveitic Macular Edema"
},
{
"lang": "CN",
"name": "葡萄膜炎黄斑水肿"
}
] | 适应症名称,引用“CommonName” |
drug_type | object | {
"display_name": [
{
"lang": "EN",
"name": "CAR-T"
},
{
"lang": "CN",
"name": "CAR-T"
}
],
"normalized_id": "e9f267acd397430897163507bc9d735d"
} | 药物类型,引用“CommonDictionary” |
organization | object | {
"organization": {
"display_name": [
{
"lang": "EN",
"name": "Hrain Biotechnology Co., Ltd."
},
{
"lang": "CN",
"name": "上海恒润达生生物科技股份有限公司"
}
],
"organization_id": "b4c624212749f84e83429c5a8673c692"
}
} | 机构,引用“CommonOrganization” |
display_name | array | [
{
"lang": "EN",
"name": "Roche Holding AG"
},
{
"lang": "CN",
"name": "罗氏"
}
] | 机构名称,引用“CommonName” |
organization_id | string | 87bfaf037f8e60c9e25595cd98bb27e4 | 机构ID |
dimension | string | ORGANIZATION | 分析维度 |
status必填 | boolean | false | 状态 |
error_msg | string | The request parameter format is incorrect! | 错误信息 |
error_code必填 | integer | 0 | 错误代码 |
成功响应示例
成功调用 API 的响应示例
JSON
{
"data": {
"items": [
{
"data": [
{
"drug": [
{
"drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
"drug_type": {
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
},
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"un_know": [
"e4cbc3790c5d4f299e8cd765585033ad"
],
"stat_info": {
"drug_type": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
}
]
},
"dev_status": {
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
},
"related_drug_id": [
"07bf6b38be634718897783feeabef441"
]
}
],
"target": {
"target_id": "1c2067e5ab054a8995f73efcfcf56207",
"short_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
},
"country": {
"country_id": "676de5ba-893a-36bb-8683-c93306aaf769",
"alpha2_code": "US",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
},
"disease": {
"disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
},
"drug_type": {
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
},
"organization": {
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
}
}
],
"dimension": "ORGANIZATION"
},
"status": true,
"error_code": 0
}错误码
此接口可能返回的错误码列表
业务错误码
| 错误码 | 描述 |
|---|---|
68300004 | 请求参数异常! |
68300005 | 查询Api失败! |
68300006 | 解析基本存取错误! |
68300007 | 存在错误的请求! |
68300008 | 服务中断异常,请稍后再试! |
68300010 | 文件不符合上传规范! |
平台错误码
| 错误码 | 描述 |
|---|---|
67200000 | API整体限流错误! |
67200001 | API整体限流错误! |
67200002 | 当前调用速率过快,超过当前配置限制QPS! |
67200003 | 申请token的key和secret传参不正确或者客户端已被禁用! |
67200004 | 请求的接口无权限请联系我们的支持人员! |
67200005 | 账户余额/调用次数不足! |
67200006 | 客户端超过开通有效期! |
67200007 | 当前调用超过当天配置使用额度! |
67200008 | 请检查query参数中必填的apikey是否传输! |
67200009 | apikey与所传的bearerToken不匹配,请检查是否使用在有效期内的token! |
67200012 | 请求不合法! |
67200100 | 当前服务器状态正忙,请求响应超时! |
67200101 | 当前请求的Api不存在请检查请求Path! |
HTTP 状态码
| 状态码 | 描述 |
|---|---|
0 | 请求成功 |
201 | Created |
401 | Unauthorized |
403 | Forbidden |
404 | Not Found |
性能指标
此接口的预期性能特征
正常响应时间
5000 ms
最大响应时间
10000 ms